title: Improved blood glucose control by insulin therapy in type 2 diabetic patients has no effect on lipoprotein(a) levels.
abstract: The effects of improved blood glucose control by insulin therapy on lipoprotein(a) and other lipoproteins were studied in 54 patients with Type 2 diabetes (mean +/- SD: age 67 +/- 9 years, body mass index 26.1 +/- 4.4 kg m-2, median duration of diabetes 10 (range 1-37) years, 23 males, 31 females), who were poorly controlled despite diet and maximal doses of oral hypoglycaemic agents. After 6 months of insulin treatment, mean fasting blood glucose concentrations had decreased from 14.1 +/- 2.2 mmol l-1 to 8.4 +/- 1.8 mmol l-1 (p < 0.001), and HbA1c had fallen from 11.1 +/- 1.4% to 8.2 +/- 1.1% (p < 0.001). Significant decreases of total and LDL cholesterol, triglycerides, apolipoprotein B, and free fatty acids were observed, while HDL-cholesterol and apoA1 increased by 10%. Baseline serum Lp(a) levels were elevated compared to non-diabetic subjects of similar age (median 283, range 8-3050 mg l-1, vs 101, range 8-1747 mg l-1, p < 0.05), but did not change with insulin, and there was no correlation with the degree of metabolic improvement and changes in Lp(a) levels. It is concluded that improved blood glucose control by insulin therapy does not alter elevated Lp(a) levels in Type 2 diabetic patients, but has favourable effects on the other lipoproteins.
authors.affiliation: Department of Internal Medicine, University Hospital Maastricht, The Netherlands.
authors.forename: B H
authors.initials: BH
authors.lastname: Wolffenbuttel
authors.forename: P B
authors.initials: PB
authors.lastname: Leurs
authors.forename: J P
authors.initials: JP
authors.lastname: Sels
authors.forename: G J
authors.initials: GJ
authors.lastname: Rondas-Colbers
authors.forename: P P
authors.initials: PP
authors.lastname: Menheere
authors.forename: A C
authors.initials: AC
authors.lastname: Nieuwenhuijzen Kruseman
mesh_terms: D000368:Aged; D016632:Apolipoprotein A-I / Q000378:metabolism; D001055:Apolipoproteins B / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism*; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D017270:Lipoprotein(a) / Q000097:blood*; D008297:Male; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D001786:Blood Glucose; D002784:Cholesterol; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D005230:Fatty Acids, Nonesterified; D006442:Glycated Hemoglobin; D007328:Insulin; D008055:Lipids; D017270:Lipoprotein(a); D014280:Triglycerides